Ballicules.com

Dextroamphetamine IR tablets

ZENZEDI

What it isDextroamphetamine IR tablets (ZENZEDI, 2013) — Seven strengths, 2.5-30 mg.

Why this oneDuration of action 3-5 h (Carlat Table 1); same molecule and elimination kinetics as the parent — the formulation is the difference.

What limits itApproved ages (ADHD label): 3-16. Class warnings of the parent molecule apply.

FDA-approved for

FDA label

BOXED WARNING Abuse, misuse, and addiction
FDA dosingPopulationStartTargetMax
NarcolepsyAdults and pediatric ≥6 y5 mg/day (6–12 y) or 10 mg/day (≥12 y)5–60 mg/day in divided doses60 mg/day
Attention Deficit Disorder with HyperactivityPediatric 3–16 y2.5 mg/day (3–5 y) or 5 mg QD–BID (≥6 y)40 mg/day

Titration Increase in weekly increments (2.5 mg for 3–5 y; 5 mg for ≥6 y / 6–12 y narcolepsy; 10 mg for ≥12 y narcolepsy)

Renal Undefined

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Pregnancy Category C; use only if potential benefit justifies risk to fetus

Lactation Amphetamines are excreted in human milk; mothers should refrain from nursing

⚠ BOXED WARNING

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Dextroamphetamine IR tablets ballicule

Dextroamphetamine IR tablets ballicule: receptor binding, kinetics and half-life diagram

Open Dextroamphetamine IR tablets in the interactive console ↗

Memory aids: mascots and interaction avatars

Dextroamphetamine IR tablets DEXEDRINE mascot mnemonic cartoon
“Dexter amphetamine”

Open Dextroamphetamine IR tablets in the interactive console ↗